Exendin-4 is a 39 aa polypeptide and incretin mimetic which was first isolated from Gila monster saliva. The synthetic form, Exenatide, is a glucagon like peptide-1 (GLP-1) agonist approved for the treatment of diabetes mellitus type II. Research shows Exendin-4 is involved in glucose-dependent enhancement of insulin secretion, reduction of hyperglycemia, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake, often with body weight reduction or blunting of weight gain.
Product Details
| Alternative Name: | Exenatide |
| |
| Sequence: | His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| |
| MW: | 4186.57 |
| |
| Source: | Synthetic. |
| |
| CAS: | 141758-74-9 |
| |
| Formulation: | Lyophilized. |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in water or DMSO. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Pancreas agenesis mutations disrupt a lead enhancer controlling a developmental enhancer cluster: I.M. Escalada, et al.; Dev. Cell
57, 1922 (2022),
Abstract;
Evolution of Exenatide as a Diabetes Therapeutic: S. Bhavsar, et al.; Curr. Diabetes Rev.
9, 161 (2013),
Abstract;
Full Text
The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide: A. H. Barnett, et al.; Diabetes Obes Metab.
14, 304 (2011),
Abstract;
Full Text
Related Products
